| Periods | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 3 Years | All Time |
|---|---|---|---|---|---|---|---|
| Primex-40 | |||||||
| Celestial Biolabs Limited |
|
Particulars |
31-03-2019 |
31-03-2018 |
|
EQUITY AND LIABILITY |
|
|
|
Equity Share Capital |
2,258.63 |
2,258.63 |
|
Other equity |
7,968.67 |
7,971.47 |
|
Total equity |
10,227.30 |
10,230.10 |
|
Non-Current Liabilities |
|
|
|
Borrowings |
781.65 |
482.00 |
|
Deferred tax liabilities |
140.52 |
-2.65 |
|
Current Liabilities |
|
|
|
Dues of creditors other than, micro-enterprises and small enterprises |
55.79 |
43.36 |
|
other financial liabilities |
567.35 |
470.00 |
|
provisions |
12.22 |
17.59 |
|
income tax liabilities |
148.31 |
155.05 |
|
Total liabilities |
1,705.84 |
1,165.35 |
|
TOTAL EQUITY AND LIABILITES |
11,933.14 |
11,395.45 |
|
ASSETS |
|
|
|
Non-Current Assets |
|
|
|
Property plant and equipment |
1,215.70 |
1,284.34 |
|
Capital work-in-progress |
2,955.81 |
2,955.81 |
|
Other intangible assets |
3,935.77 |
4,025.55 |
|
intangible assets under development |
1,567.81 |
488.25 |
|
other financial assets |
|
30.10 |
|
Current Assets |
9,675.09 |
8,784.05 |
|
Inventories |
613.50 |
395.77 |
|
Trade receivables |
1,563.65 |
2,076.91 |
|
Cash and cash equivalents |
5.04 |
0.99 |
|
other current assets |
75.85 |
137.74 |
|
Total current assets |
2,258.04 |
2,611.41 |
|
TOTAL ASSETS |
11,933.13 |
11,395.45 |
|
Particulars |
31-03-2019 |
31-03-2018 |
|
Revenue from operations |
4,897.42 |
4,281.46 |
|
other income |
35.65 |
0.04 |
|
Total revenue |
4,933.07 |
4,281.50 |
|
Expenses |
|
|
|
cost of material consumed |
51.40 |
10.80 |
|
purchase of stock in trade |
3,070.24 |
2,490.61 |
|
changes in inventories of finished goods, work-in-progress and stock-in-trade |
-251.56 |
366.59 |
|
employee benefits expenses |
148.19 |
63.40 |
|
finance costs |
125.05 |
2.54 |
|
depreciation and amortisation expenses |
944.13 |
769.54 |
|
other expenses |
705.27 |
167.16 |
|
total expenses |
4,792.72 |
3,870.64 |
|
profit before tax for the year |
140.35 |
410.86 |
|
current tax |
|
78.29 |
|
differed tax |
-143.17 |
13.06 |
|
Total comprehensive income for the years |
|
|
|
earning per equity share of face value |
|
|
|
basic |
-0.01 |
1.53 |
|
diluted |
-0.01 |
1.53 |
|
Particulars |
31-03-2019 |
31-03-2018 |
|
CASH FLOW FROM OPERATING ACTIVITY |
|
|
|
Net Profit before Tax |
140.36 |
410.86 |
|
Depreciation |
944.13 |
769.54 |
|
interest and financial charges paid |
125.05 |
2.54 |
|
differed tax |
|
13.06 |
|
provision for tax |
|
-78.29 |
|
Operating Profit before Working Capital Charges |
1,209.54 |
1,117.71 |
|
(increase)/decrease in inventory |
-217.73 |
376.00 |
|
(increase)/decrease in trade receivables |
513.26 |
-1,251.29 |
|
(increase)/decrease in other current assets |
61.90 |
|
|
(increase)/decrease in trade payables |
12.43 |
0.98 |
|
(increase)/decrease in other financial liabilities |
97.63 |
|
|
(increase)/decrease in other current liabilities |
-5.37 |
12.90 |
|
(increase)/decrease in provisions |
-6.74 |
77.35 |
|
Cash generated from operating activities |
1,664.92 |
333.65 |
|
CASH FLOW FROM INVESTING ACTIVITIES |
|
|
|
Purchase of fixed assets |
-0.26 |
|
|
intangible assets under development |
-1,079.56 |
|
|
product development expenses |
-785.73 |
-488.25 |
|
Net Cash Flow from Investing Activities |
-1,865.55 |
-488.25 |
|
CASH FLOW FROM FINANCING ACTIVITIES |
|
|
|
Increase/(Decrease) in borrowings |
299.65 |
-300.00 |
|
Increase/(Decrease) in other financial assets |
30.10 |
|
|
Increase/(Decrease) in unsecured loans |
|
417.00 |
|
interest and financial charges paid |
-125.05 |
-2.54 |
|
Net Cash Flow/(used) From Financing Activities |
204.70 |
114.46 |
|
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS |
4.07 |
-40.14 |
|
CASH & CASD EQUIVALENTS AT THE BEGINNING OF THE YEAR |
0.99 |
41.13 |
|
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR |
5.06 |
0.99 |
The need for herbal and natural solutions for a range of health issues has led to a strong growth in the Indian herbal supplements market in recent years. At USD 5.26 billion in 2017, the size of the global market for herbal supplements was projected to increase at a compound annual growth rate (CAGR) of 6.2% over the forecast period. A few of the major drivers driving the market expansion include the growing popularity of natural products, increased awareness of preventative healthcare, and rising health and wellness expenditures. The size of the world market for herbal medicines was estimated at $216.40 billion in 2023 and is expected to increase to $437 billion by 2032 from $233.08 billion in 2024. The market for herbal medicines is expected to increase from $233.08 billion to $216.40 billion by 2023.
Q.1 Do Celestial Biolabs Limited is listed or not?
Celestial Biolabs Limited is unlisted company.
Q.2 Is Celestial Biolabs Limited is profitable?
The company has shown an increasing profit and good cash flow statement position.
Q.3 when did Celestial Biolabs Limited gets delisted?
SEBI passed an order to celestial biolabs limited on 5th of October 2018.
Q.4 What is the main Work of Celestial Biolabs Limited?
Herbal and feed supplement formulations is the main work of celestial biolabs limited.
